Literature DB >> 2049576

Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive associations with HLA-DR4, DR1 and DRw10.

B P Wordsworth1, J Stedeford, W M Rosenberg, J I Bell.   

Abstract

Most patients with rheumatoid arthritis (RA) exhibit an HLA class II epitope found on most DR4 and DR1 molecules. We have investigated the possibility of other associations being present in the minority of patients lacking these antigens. One hundred and eighty patients with classical or definite RA and 100 controls were assigned HLA-DR, DQ and DP types by a DNA-based system using sequence-specific oligonucleotides to probe amplified class II alleles amplified by the polymerase chain reaction. The expected associations with DR4 (relative risk 10, P less than 0.0001) and DR1 (relative risk 2.3, P less than 0.001) were observed and only 13% of individuals lacked both of these alleles compared with 54% of age- and race-matched controls. A significant association with DRw10 (P = 0.02) was also observed in the DR4/DR1-negative RA group (3/23 patients compared with 0/54 DR4/DR1-negative controls). No novel associations with other DR, DQ, or DP alleles were evident in contrast to some previous studies. The third allelic hypervariable region of the DR beta chain of DRw10 contains a similar amino acid sequence to that found in many DR4 and DR1 molecules. These results extend this correlation and suggest that this susceptibility determinant may account for the HLA-linked susceptibility in 89% of our cases of RA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049576     DOI: 10.1093/rheumatology/30.3.178

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  9 in total

1.  Only weak association between disease severity and HLA-DRB 1 genes in a Swiss population of rheumatoid arthritis patients.

Authors:  M Seitz; M Perler; W Pichler
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

2.  Predominance of HLA-DRB1*0405 in Korean patients with rheumatoid arthritis.

Authors:  H Y Kim; T G Kim; S H Park; S H Lee; C S Cho; H Han
Journal:  Ann Rheum Dis       Date:  1995-12       Impact factor: 19.103

3.  Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis.

Authors:  K Eberhardt; E Fex; U Johnson; F A Wollheim
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

4.  Sex influences on the penetrance of HLA shared-epitope genotypes for rheumatoid arthritis.

Authors:  J M Meyer; J Han; R Singh; G Moxley
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

5.  Influence of non-inherited maternal HLA-DR antigens on susceptibility to rheumatoid arthritis.

Authors:  I E van der Horst-Bruinsma; J M Hazes; G M Schreuder; T R Radstake; P Barrera; L B van de Putte; D Mustamu; D van Schaardenburg; F C Breedveld; R R de Vries
Journal:  Ann Rheum Dis       Date:  1998-11       Impact factor: 19.103

6.  Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis.

Authors:  P Emery; M Salmon; H Bradley; P Wordsworth; E Tunn; P A Bacon; R Waring
Journal:  BMJ       Date:  1992-12-05

7.  HLA heterozygosity contributes to susceptibility to rheumatoid arthritis.

Authors:  P Wordsworth; K D Pile; J D Buckely; J S Lanchbury; B Ollier; M Lathrop; J I Bell
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

8.  Citrullination only infrequently impacts peptide binding to HLA class II MHC.

Authors:  John Sidney; Stephane Becart; Mimi Zhou; Karen Duffy; Mikaela Lindvall; Erin C Moore; Eugene L Moore; Tadimeti Rao; Navin Rao; Morten Nielsen; Bjoern Peters; Alessandro Sette
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

9.  Association of rheumatoid arthritis and its severity with human leukocytic antigen-DRB1 alleles in Kurdish region in North of Iraq.

Authors:  Niaz Albarzinji; Sherzad Ali Ismael; Dashty Albustany
Journal:  BMC Rheumatol       Date:  2022-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.